Viridicatin from the Antarctic Fungus Penicillium sp. Protects Human Microglia and Patient-Derived Peripheral Immune Cells Against Oxidative Stress
Authors:
- Cristian PazCristian Paz
- Muhammad Javid IqbalMuhammad Javid Iqbal
- Andrea Cristina Paula LimaAndrea Cristina Paula Lima
- Alejandro LuarteALAlejandro Luarte
- Pablo LazcanoPLPablo Lazcano
- Ursula WynekenUWUrsula Wyneken
- María Isabel BehrensMBMaría Isabel Behrens
- Daniela PonceDPDaniela Ponce
- Nicole JeraldoNJNicole Jeraldo
- Sigisfredo GarnicaSGSigisfredo Garnica
- Cecilia VillegasCVCecilia Villegas
- Vaderament-A. Nchiozem-NgnitedemVNVaderament-A. Nchiozem-Ngnitedem
Open Access
- 30 August 2026
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 15 (9) , 1089
Abstract
Neurodegenerative diseases remain a major therapeutic challenge, with oxidative stress playing a central role in central and peripheral immune system dysfunction that leads to neuronal loss. Natural products from extreme environments represent an underexplored source of neuroprotective agents. In this study, viridicatin, a quinoline-derived alkaloid, was isolated from the Antarctic fungus Penicillium sp. collected from sediments taken from Deception Island, and its structure was unambiguously confirmed by 1D/2D-NMR spectroscopy and single-crystal X-ray diffraction. Viridicatin (100 µM) significantly attenuated H2O2-induced cytotoxicity in HMC-3 human microglial cells, preserving cell viability and mitochondrial membrane potential. Viridicatin modulated the Nrf2 antioxidant signaling pathway, accompanied by increased expression of the downstream antioxidant enzymes HO-1 and NQO1. Moreover, molecular docking revealed preferential binding to the KEAP1 Kelch domain (−8.0 kcal/mol), suggesting indirect Nrf2 pathway modulation. A 100 ns molecular dynamics simulation with MM-GBSA analysis supported the stability of the viridicatin–KEAP1 complex. Notably, viridicatin rescued peripheral immune cells, i.e., peripheral blood mononuclear cells (PBMCs) obtained from older adults with mild cognitive impairment from H2O2-induced cell death, bridging the gap between in vitro mechanistic evidence and clinically relevant human cellular models. This is the first report of neuroprotective activity for viridicatin, positioning this Antarctic-derived alkaloid as a compelling candidate for further preclinical development against age-related neurodegeneration.Keywords
Funding Information
- Institut chilien de l'Antarctique (RG-08-24)
- Institut chilien de l'Antarctique (DG-08-23)
- Agencia Nacional de Investigación y Desarrollo (11250944)
- Universidad de La Frontera
This publication has 58 references indexed in Scilit:
- Integrated computational and experimental evaluation of grossamide as a natural product scaffold for dual carbohydrase inhibition in diabetesJournal of Computer-Aided Molecular Design, 2025
- Co-occurrence of mycotoxins and other fungal metabolites in total mixed rations of cows from dairy farms in Punjab, PakistanMycotoxin Research, 2023
- Role of Nrf2 in aging, Alzheimer’s and other neurodegenerative diseasesAgeing Research Reviews, 2022
- Oxidants in Physiological Processes2020
- Reactive oxygen species-responsive drug delivery systems for the treatment of neurodegenerative diseasesBiomaterials, 2019
- Viridicatol and viridicatin isolated from a shark-gill-derived fungus Penicilliumpolonicum AP2T1 as MMP-2 and MMP-9 inhibitors in HT1080 cells by MAPKs signaling pathway and docking studiesMedicinal Chemistry Research, 2019
- Effect of environmental parameters on biodiversity of the fungal component in lithic Antarctic communitiesExtremophiles, 2017
- On the Dependency of Cellular Protein Levels on mRNA AbundanceCell, 2016
- Life and Death of MicrogliaJournal of Neuroimmune Pharmacology, 2009
- Nrf2–Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen speciesAdvances in Enzyme Regulation, 2006